Figures Legends :
Figure 1: B cell response by Neutralizing IgG Antibodies in Pediatric Cancer Patients compared to Healthy Controls. Quantitative neutralizing antibody response at each time point after vaccination compared to healthy controls. Please note that healthy controls only had one time point and for optimal visualization, is presented in a linear fashion over each time point (red line). A. Pediatric cancer patients with adequate B cell response. B. Pediatric cancer patients with inadequate B cell response.
Figure 2: Evaluation of clinical factors that may response to SARS-COV2 vaccination . A . B cell response after vaccination in leukemia/lymphoma patients (upper) and solid tumor patients (lower). B. Comparison of absolute lymphocyte counts prior to vaccination (0 week) and 8-12 weeks post vaccination in the adequate vs inadequate response groups. There was no statistical significance between any of the groups (Adequate response 0 wk and inadequate response 0 wk, p = 0.86; Adequate response 8 wk and inadequate response 8 wk, p = 0.99; adequate response 0 wk and adequate response 8 wk, p = 0.75; inadequate response 0 wk and adequate response 8 wk, p = 0.79).C. B cell response after vaccination in patients with highly myelosuppressive (upper) and less myelosuppressive (lower) chemotherapy. There was no statistical difference in neutralizing antibodies between both therapy groups (2 wk, p = 0.859; 4-6 wk, p = 0.740, 8-12 wk, p = 0.758).